In this retrospective cohort study, liver resection (LR) showed higher 1-, 3-, and 5-year survival rates than percutaneous radiofrequency ablation (PRFA) or transarterial chemoembolization (TACE).
NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk ...
Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable primary hepatocellular carcinoma with high risk of recurrence: A ...
PET-CT imaging with [18 F]fluorodeoxyglucose (FDG) and [18 F]fluorocholine (FCH) altered treatment plans in only a tiny minority of patients undergoing initial staging for hepatocellular carcinoma ...
Patients who are not eligible for surgical resection may or may not be eligible for liver transplant, depending on the extent of their disease, as outlined by the Milan and other criteria above. Some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results